Vertex Wins Approval for Kalydeco to Treat Cystic Fibrosis
This article is for subscribers only.
Vertex Pharmaceuticals Inc. won approval of the first drug to treat the underlying cause of cystic fibrosis.
The Food and Drug Administration cleared Kalydeco for a rare form of cystic fibrosis in patients ages 6 and older who have a specific gene mutation, the agency said today in a statement. Cystic fibrosis is the most-common fatal genetic disease in the Caucasian population, the FDA said.